精准免疫肿瘤市场规模、份额和成长分析（按癌症类型、治疗方法、生物标记、最终用途和地区划分）—产业预测（2026-2033 年）

全球精准免疫肿瘤学市场预计到 2024 年将达到 672 亿美元，到 2025 年将达到 744.6 亿美元，到 2033 年将达到 1,691.3 亿美元，预测期（2026-2033 年）的复合年增长率为 10.8%。

精准免疫肿瘤学作为一种革命性的癌症治疗方法，正迅速崛起，其核心在于根据患者的基因谱、肿瘤特征和免疫反应量身定制个人化治疗方案。这种创新策略不仅能提高治疗效果，促进长期缓解，而且与传统疗法相比，还能显着降低副作用。借助先进的诊断工具，医生可以识别癌细胞内的特定基因突变和独特标誌物，从而实现精准标靶治疗治疗，为患者提供个人化治疗。精准免疫肿瘤学能够在改善患者预后的同时保护健康组织，其优势凸显，并在製药业催生了一个蓬勃发展的市场。该领域不断增长的投资和研究也表明，人们通用认为精准免疫肿瘤学能够重塑癌症治疗模式。

全球精准免疫肿瘤市场驱动因素

全球癌症发生率的不断攀升仍然是一项重大的公共卫生挑战，也因此推动了更有效治疗方法的需求。传统的治疗方法，例如化疗和放射线治疗，有许多局限性，并可能为患者带来严重的副作用。相较之下，精准免疫肿瘤学是一种突破性的策略，它利用个体自身免疫系统的力量来更有效地攻击癌细胞。随着对先进的个人化治疗方法的需求日益增长，精准免疫肿瘤学已成为市场的重要驱动力，它有望根据患者的基因谱和肿瘤特征量身定制治疗方案，最终在改善治疗效果的同时，最大限度地减少传统疗法带来的不良副作用。

限制全球精准免疫肿瘤市场发展的因素

精准免疫肿瘤学市场面临的一大挑战是这些创新疗法的高昂成本。与传统癌症治疗不同，精准免疫肿瘤学需要个人化治疗方案和复杂的调查方法，这会导致高昂的费用。这种经济负担会限制患者获得治疗的机会，尤其是在医疗资源有限的发展中地区。导致成本上升的因素有很多，包括大规模的研发投入、对先进医疗设备的需求以及用于筛选合格患者的生物标记检测。因此，高昂的治疗费用会导致治疗机会的不平等，尤其是在中低收入患者群体中，并阻碍公平的癌症治疗和治疗效果。

全球精准免疫肿瘤市场趋势

全球精准免疫肿瘤市场正呈现显着的联合治疗趋势，将免疫疗法与化疗、放射线治疗等传统疗法结合。这种多管齐下的治疗方法充分发挥每种治疗方法的优势，不仅能缩小肿瘤，还能活化患者自身的免疫系统，有效标靶并清除癌细胞，进而提高治疗效果。随着对单一治疗方法的抗药性日益凸显，联合治疗策略的应用正受到越来越多的关注，使肿瘤学家能够绕过适应性抗药性机制，并透过多种生物学途径扩大对癌症的治疗范围。这项发展有望重新定义癌症治疗，并显着改善患者的预后。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术分析
• 专利分析
• 研发线产品分析
• 案例研究分析

全球精准免疫肿瘤市场规模（依癌症类型划分）及复合年增长率（2026-2033 年）

• 肺癌
• 乳癌
• 摄护腺癌
• 黑色素瘤
• 其他的

全球精准免疫肿瘤市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 查核点抑制剂
• CAR-T细胞疗法
• 癌症疫苗
• 其他的

全球精准免疫肿瘤市场规模（按生物标记和复合年增长率划分）（2026-2033 年）

• PD-L1
• BRCA
• KRAS
• EGFR
• 其他的

全球精准免疫肿瘤市场规模（依最终用途及复合年增长率划分）（2026-2033 年）

• 医院
• 诊所
• 研究所
• 其他的

全球精准免疫肿瘤市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Adaptimmune Therapeutics plc（UK）
• Agenus Inc.（US）
• Amgen Inc.（US）
• AstraZeneca plc（UK）
• Bristol Myers Squibb Company（US）
• Celgene Corporation（US）
• Eli Lilly and Company（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Gilead Sciences, Inc.（US）
• GlaxoSmithKline plc（UK）
• Iovance Biotherapeutics, Inc.（US）
• Juno Therapeutics, Inc.（US）
• Kite Pharma, Inc.（US）
• Merck & Co., Inc.（US）
• Neon Therapeutics, Inc.（US）
• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• Sanofi SA（France）
• Seattle Genetics, Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）

结论与建议

Global Precision Immuno-Oncology Market size was valued at USD 67.2 Billion in 2024 and is poised to grow from USD 74.46 Billion in 2025 to USD 169.13 Billion by 2033, growing at a CAGR of 10.8% during the forecast period (2026-2033).

Precision immuno-oncology is rapidly gaining traction as a transformative approach in cancer treatment, focusing on individualized therapies tailored to patients' genetic profiles, tumor characteristics, and immune responses. This innovative strategy not only enhances treatment efficacy and fosters long-term remissions but also significantly minimizes side effects compared to traditional methods. Utilizing advanced diagnostic tools, physicians can identify specific genetic mutations and unique markers within cancer cells, allowing for precise targeting by tailored therapies. The potential to improve patient outcomes while preserving healthy tissue underscores its appeal, leading to a burgeoning market within the pharmaceutical sector. Increasing investments and research in this domain highlight a collective recognition of precision immuno-oncology's capacity to redefine the landscape of cancer care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segments Analysis

Global Precision Immuno-Oncology Market is segmented by cancer type, treatment type, biomarker, end use and region. Based on cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma and others. Based on treatment type, the market is segmented into checkpoint inhibitors, Car T Cell Therapy, cancer vaccines and others. Based on biomarker, the market is segmented into PD-L1, BRCA, KRAS, EGFR and others. Based on end use, the market is segmented into hospital, clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Precision Immuno-Oncology Market

The global rise in cancer incidence remains a significant public health challenge, leading to an increased demand for more effective treatment options. Traditional therapies, such as chemotherapy and radiation, often come with considerable limitations and can impose severe side effects on patients. In contrast, precision immuno-oncology represents a groundbreaking strategy that harnesses the power of an individual's immune system to combat cancer more effectively. As the need for advanced and tailored therapies rises, precision immuno-oncology stands out as a pivotal force in the market, promising personalized treatments that align with a patient's genetic profile and tumor characteristics, ultimately enhancing outcomes while minimizing adverse effects associated with conventional methods.

Restraints in the Global Precision Immuno-Oncology Market

A significant challenge in the precision immuno-oncology market is the high cost associated with these innovative therapies. Unlike traditional cancer treatments, precision immuno-oncology involves a personalized approach and complex methodologies, making it often more expensive. This financial burden can restrict patient access, particularly for those in developing regions with limited healthcare resources. Various elements contribute to the elevated costs, including extensive research and development investments, the need for advanced medical equipment, and the utilization of biomarker testing to select appropriate candidates for treatment. Consequently, the high price tag can lead to disparities in treatment availability, especially among low- and middle-income populations, ultimately hindering equitable cancer care and outcomes.

Market Trends of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is experiencing a notable trend towards combination therapies that integrate immunotherapy with traditional treatments like chemotherapy and radiation. This multifaceted approach enhances treatment efficacy, leveraging the strengths of each modality to not only shrink tumors but also empower the patient's immune system to effectively target and eliminate cancer cells. As resistance to individual therapies becomes a significant challenge, the use of combinatorial strategies is gaining traction, enabling oncologists to circumvent adaptive resistance mechanisms and broaden the therapeutic attack on cancer through various biological pathways. This evolution is poised to redefine cancer care and improve patient outcomes significantly.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Pipeline Product Analysis
• Case Study Analysis

Global Precision Immuno-Oncology Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Melanoma
• Others

Global Precision Immuno-Oncology Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Checkpoint Inhibitors
• Car T Cell Therapy
• Cancer Vaccines
• Others

Global Precision Immuno-Oncology Market Size by Biomarker & CAGR (2026-2033)

• Market Overview
• PD-L1
• BRCA
• KRAS
• EGFR
• Others

Global Precision Immuno-Oncology Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospital
• Clinics
• Research Institutes
• Others

Global Precision Immuno-Oncology Market Size & CAGR (2026-2033)

• North America (Cancer Type, Treatment Type, Biomarker, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment Type, Biomarker, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment Type, Biomarker, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment Type, Biomarker, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment Type, Biomarker, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neon Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seattle Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations